Uncategorized

Celon Pharma S.A. decided to voluntarily withdraw three batches of Salmex (500 µg + 50 µg), used in treatment of asthma and COPD, from the market. Despite this fact, availability of the product for patients remains stable. Salmex (500 µg + 50 µg)/ inhalation dose were withdrawn. BATCH NUMBER EXPIRY DATE 223044015 12.2016 223036115 11.2016Read more »

The III World Spirometry Days take place between 14 and 19 September 2015, which offer the chance to take a free-of-charge spirometry test. The III World Spirometry Days are organised by the Polish Federation of Asthma, Allergy and COPD Patients’ Organisations. Spirometry tests constitute an important element in the prevention of pulmonary diseases. This testRead more »

Among the participants of the 20th European Hematology Association (EHA) Congress which took place on 11-14 June in Vienna were also representatives of Celon Pharma S.A. This year, the Company presented the latest results of research on the development of potential drugs for treatment of leukemias and lymphomas. The data was presented in the formRead more »

The scientific-business consortium lead by Celon Pharma S.A. received funding from the National Centre for Research and Development (NCRD) as part of the STRATEGMED programme for the development of another innovative project: “Development of novel biomarkers and innovative FGFR kinases inhibitor as an anti-cancer therapy” (CELONKO). Celon Pharma will lead the “Development of modern novelRead more »

For the second time Celon Pharma will participate in the European Respiratory Congress (ERS), which is the meeting place for international leaders behind the most interesting scientific discoveries – this time held in Amsterdam. Last year the Congress was held in Munich and was participated by 21 958 delegates and 195 exhibitors, while Celon Pharma’sRead more »

Celon Pharma S.A. will present the results of its research on innovative kinase inhibitors at the European Society for Medical Oncology (ESMO) Congress which will be held in Madrid on 26-30 September 2014. We encourage participants of the Congress to examine our poster entitled: “Preclinical evaluation of a novel, selective pan-FGFR kinase inhibitor CPL-304-110 asRead more »

Celon Pharma S.A. is going to present the latest data on proprietary innovative phosphodiesterase 9 inhibitors at AAIC in Copenhagen that is scheduled from 12th to 17th of July 2014. Conference attendees are welcome to visit our researchers at the poster entitled: “Characterization of a novel group of phosphodiesterase 9A inhibitors as putative therapeutic forRead more »

Celon Pharma S.A. received the Wprost Innovator 2013 in the “Pharmacy and Medicine” category. Thus the company confirmed it belongs to one of the most innovative companies in Poland.  The ranking of the most innovative Polish companies is prepared annually by the Institute of Economic Sciences of the Polish Academy of Sciences and the editorsRead more »

Press release Warsaw, May 2013 Celon Pharma S.A. announces a competition for research projects in the field of asthma and COPD. Aim for Innovations is a nationwide competition which is a call for cooperation with industry directed at outstanding scientists in the fields of medical science, pharmaceutics, biology and biotechnology and which offers them aRead more »